Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J And AstraZeneca Warn Of Topamax/Toprol Name Confusion

This article was originally published in The Pink Sheet Daily

Executive Summary

J&J is aware of about 100 reports of medication errors that occurred due to confusion between its anti-epileptic Topamax and AstraZeneca's beta blocker Toprol XR in the eight years both drugs have been on the market.

You may also be interested in...



NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance

FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications

New Look At Ezetimibe Fails To Confirm Vytorin Cancer Signal

Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.

FDA Risk Communication Research May Follow Critical Path To Avoid OMB

FDA may need to undertake an approach similar to the agency's Critical Path initiative in order to facilitate research evaluating its communication efforts

Topics

UsernamePublicRestriction

Register

PS062954

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel